Talk to the Veterans Crisis Line now
An official website of the United States government
Search | Search by Center | Search by Source | Keywords in Title
Lamprea-Montealegre JA, Shapiro A, Bontrager NAB, Rifkin DE, Jassal SK, Gregg LP, Navaneethan SD, Navarra K, Shlipak MG, Estrella MM, Wang V. Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators. Kidney medicine. 2024 Jun 1; 6(6):100830.
Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects. RATIONALE and OBJECTIVE: The measurement of cystatin C has been recommended to enhance chronic kidney disease (CKD) detection and risk stratification in clinical practice. This study gathered insights into the perceptions and experiences of clinical staff regarding the use of cystatin C in CKD detection within the Veterans Health Administration (VHA) system. STUDY DESIGN: A qualitative approach was employed to explore barriers and facilitators of clinical staff regarding the use of cystatin C in CKD detection within the VHA system. The Organizational Theory of Implementation Effectiveness informed the development of a semistructured interview guide. SETTING and PARTICIPANTS: Health care providers, nurses, and clinical pharmacists from the VHA systems in San Francisco, San Diego, and Houston were interviewed between October 2021 and May 2022. EXPOSURES: Participants'' experiences with cystatin C testing. OUTCOMES: Perceived barriers and facilitators to cystatin C testing. ANALYTICAL APPROACH: Participant responses from individual interviews were analyzed by a multidisciplinary team using rapid qualitative analysis methods. RESULTS: Fourteen in-depth interviews were conducted across the 3 VHA systems. Ten of 11 providers worked in primary care. Five key barriers to using cystatin C for CKD detection were identified. These included lack of patient awareness of CKD testing, lack of provider awareness about cystatin C, knowledge barriers about cystatin C testing, unclear roles and ownership of CKD detection, and lack of clinic support to enhance CKD detection. Suggested interventions to overcome these barriers included educational and training programs, improved clinic workflows, and electronic health record aids to support CKD detection and use of cystatin C. LIMITATIONS: The results may not be generalizable to other health care systems outside the VHA. CONCLUSIONS: The findings indicate a need for targeted interventions such as educational and training programs, improved clinical workflows, and electronic health record aids to address barriers limiting the use of cystatin C in clinical practice for enhanced CKD detection.
